PMV Pharmaceuticals reported a significant increase in total liabilities to $54.3 million as of September 30, 2026, primarily driven by a new $43.6 million warrant liability. The company's cash and marketable securities totaled approximately $108.5 million, while the accumulated deficit grew to $517.0 million.
PMV Pharmaceuticals reported a net loss of $34.4 million for the third quarter of 2026, primarily driven by a non-cash loss related to warrant liabilities. The company ended the period with $108.5 million in cash, bolstered by a $50 million public offering in August, which is expected to fund operations into early 2028. Key clinical progress includes the completion of enrollment for the rezatapopt Phase 2 ovarian cancer cohort with an NDA submission planned for Q1 2027.
Term
Q3 2026
“The updated monotherapy interim data demonstrate the potential for rezatapopt to address a significant unmet medical need. The completed $50 million public offering also positions us well to submit an NDA in the first quarter of 2027 seeking accelerated approval for treatment of platinum-resistant/refractory ovarian cancer patients with a TP53 Y220C mutation.”
David Mack, Ph.D., President and Chief Executive Officer
PMV Pharmaceuticals appointed Dr. Matthew Eckler to its Board of Directors, effective October 1, 2026. Dr. Eckler will receive an annual cash retainer of $40,000 and was granted an initial stock option award for 84,000 shares under the company's Outside Director Compensation Policy. The appointment comes as the company prepares for a planned NDA submission for rezatapopt in early 2027.